Press release
Gossamer Bio to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September.\n\n\n\n\nCantor Global Healthcare Conference\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nDate / Time:\n\n\n\n\n\n\nSeptember 3rd, at 9:10 AM ET\n\n\n\n\n\n\n\n\nFormat:\n\n\n\n\n\n\nFireside Chat & 1x1’s\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\nNew York, NY\n\n\n\n\n\n\n\n\nWebcast Link:\n\n\n\n\n\n\nhttps://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=93028624&checkCompany=1&checkEmail=1&checkName=1\n\n\n\n\n\n\n\n\n\nWells Fargo Healthcare Conference\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nDate / Time:\n\n\n\n\n\n\nSeptember 4th\n\n\n\n\n\n\n\n\nFormat:\n\n\n\n\n\n\n1x1’s\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\nBoston, MA\n\n\n\n\n\n\n\n\n\nH.C. Wainwright 27th Annual Global Healthcare\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nDate / Time:\n\n\n\n\n\n\nSeptember 9th, at 8:00 AM ET\n\n\n\n\n\n\n\n\nFormat:\n\n\n\n\n\n\nFireside Chat & 1x1’s\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n\nNew York, NY\n\n\n\n\n\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250829692001/en/\n\nFor Investors and Media\nBryan Giraudo, Chief Operating Officer and Chief Financial Officer\nGossamer Bio Investor Relations\[email protected]\n\n\nSource: Gossamer Bio, Inc.","length":8299,"tagName":"div"}]